Reagents and instruments for immunology, cell biology and molecular biology.
 
> Tocilizumab [375823-41-9]

Tocilizumab [375823-41-9]

Print Print
Please log in

Cat# HY-P9917-5mg

Size : 5mg

Brand : MedChemExpress

Contact local distributor :


Phone : +1 850 650 7790

Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis. Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease).

For research use only. We do not sell to patients.

Tocilizumab Chemical Structure

Tocilizumab Chemical Structure

CAS No. : 375823-41-9

This product is a controlled substance and not for sale in your territory.

Based on 20 publication(s) in Google Scholar

Description

Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis[1]. Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease)[4].

Isotype

Human IgG1 kappa
Recommend Isotype Controls

Human IgG1 kappa, Isotype Control
Species

Humanized
IC50 & Target[1][2]

IL-6

 

In Vitro

Tocilizumab (Anti-Human IL6R, Humanized Antibody) (1-100 ng/mL; 24 hours, 48 hours) inhibits the cell proliferation (growth rate) in a dose-dependent manner, growth rate by HACM is reduced almost completely by 100 ng/mL tocilizumab[2].
Tocilizumab (Anti-Human IL6R, Humanized Antibody) (0.001-10,000 μg/ml; 2 days) inhibits Ba/F3-gp130-IL-6R cell proliferation stimulated with hIL-6 with an IC50 of 13.5 ng/ml[1].
Tocilizumab (Anti-Human IL6R, Humanized Antibody) (1 μM; 6 hours) reduces the phosphorylation of STAT3 in vitro consistent with in vivo SAS cells[3].
Tocilizumab (Anti-Human IL6R, Humanized Antibody) (1-5 μM; 24 hours) significantly reduces VEGF mRNA expression in SAS cells with serum-free medium[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Tocilizumab Related Antibodies

Cell Proliferation Assay[2]

Cell Line: Human-derived HARA-B cells
Concentration: 1 ng/mL, 10 ng/mL, and 100 ng/mL
Incubation Time: 24 hours, 48 hours
Result: Inhibited the IL-6R expressed on human-derived HARA-B cells.

Cell Cytotoxicity Assay[1]

Cell Line: Ba/F3-gp130-IL-6R cells
Concentration: 0.001–10000 μg/ml
Incubation Time: 2 days
Result: Inhibited Ba/F3-gp130-IL-6R cell proliferation.

Western Blot Analysis[3]

Cell Line: SAS cells
Concentration: 1 μM
Incubation Time: 6 hours
Result: Reduced the phosphorylation of STAT3.

RT-PCR[3]

Cell Line: SAS cells
Concentration: 1-5 μM
Incubation Time: 24 hours
Result: Reduced VEGF mRNA expression.
In Vivo

Tocilizumab (Anti-Human IL6R, Humanized Antibody) (intravenous injection; 1.0 mg/100 μL; twice a week, three weeks) decreases the volume of each metastatic focus in tocilizumab-injected mouse brains[2].
Tocilizumab (Anti-Human IL6R, Humanized Antibody) (intraperitoneal injection;100 μg/mL, every 48 hours; 20days) suppresses OSCC progression and suppresses Tumor Angiogenesis[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: A brain metastasis model of lung tumor cells by inoculating HARA-B cells in nude mice[2]
Dosage: 1.0 mg/100 μL
Administration: Intravenous injection; 1.0 mg/100 μL; twice a week, three weeks
Result: Led the volume of each metastatic focus significantly smaller.
Animal Model: SCID mice with SAS cells[3]
Dosage: 100 μg/mL
Administration: Intraperitoneal injection;100 μg/mL; every 48 hours; 20days
Result: Suppressed the growth of advanced tumors.
Clinical Trial
CAS No.

375823-41-9
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Tocilizumab]
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation

Purity: 99.67%

COA (231 KB) SDS-PAGE (85 KB)

Handling Instructions (2659 KB)
References

  • [1]. Garbers C, et al. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem. 2011 Dec 16;286(50):42959-70.  [Content Brief]

    [2]. Mami Noda, et al. IL-6 Receptor Is a Possible Target against Growth of Metastasized Lung Tumor Cells in the Brain. Int J Mol Sci. 2013 Jan; 14(1): 515–526.  [Content Brief]

    [3]. Shinriki S, et al. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivogrowth of human oral squamous cell carcinoma. Clin Cancer Res. 2009 Sep 1;15(17):5426-34.  [Content Brief]

    [4]. Chi Zhang, et al. Cytokine Release Syndrome in Severe COVID-19: Interleukin-6 Receptor Antagonist Tocilizumab May Be the Key to Reduce Mortality. Int J Antimicrob Agents. 2020 May;55(5):105954.  [Content Brief]

  • [1]. Garbers C, et al. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem. 2011 Dec 16;286(50):42959-70.

    [2]. Mami Noda, et al. IL-6 Receptor Is a Possible Target against Growth of Metastasized Lung Tumor Cells in the Brain. Int J Mol Sci. 2013 Jan; 14(1): 515–526.

    [3]. Shinriki S, et al. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivogrowth of human oral squamous cell carcinoma. Clin Cancer Res. 2009 Sep 1;15(17):5426-34.

    [4]. Chi Zhang, et al. Cytokine Release Syndrome in Severe COVID-19: Interleukin-6 Receptor Antagonist Tocilizumab May Be the Key to Reduce Mortality. Int J Antimicrob Agents. 2020 May;55(5):105954.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Tocilizumab Related Classifications

  • Immunology/Inflammation
  • Interleukin Related

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Tocilizumab375823-41-9Anti-Human IL6R, Humanized AntibodyInterleukin RelatedILantibodyIL-6RNeutralizingrheumatoidarthritisSARS-CoV-2coronavirus diseaserespiratory failuredyspnoeaCOVID-19Inhibitorinhibitorinhibit

You might also be interested by the following products:



Cat#
Description
Cond.
Price Bef. VAT
HY-P7033-100ug
IL-13, Human (114a.a, CHO)
 100ug 
HY-P7033-10ug
IL-13, Human (114a.a, CHO)
 10ug 
HY-P7033-50ug
IL-13, Human (114a.a, CHO)
 50ug